ZA202203730B - Lassavirus vaccines - Google Patents
Lassavirus vaccinesInfo
- Publication number
- ZA202203730B ZA202203730B ZA2022/03730A ZA202203730A ZA202203730B ZA 202203730 B ZA202203730 B ZA 202203730B ZA 2022/03730 A ZA2022/03730 A ZA 2022/03730A ZA 202203730 A ZA202203730 A ZA 202203730A ZA 202203730 B ZA202203730 B ZA 202203730B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein
- flavivirus
- sequence
- terminally
- signal peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19197202 | 2019-09-13 | ||
| PCT/EP2020/075541 WO2021048402A1 (en) | 2019-09-13 | 2020-09-11 | Lassavirus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202203730B true ZA202203730B (en) | 2025-09-25 |
Family
ID=68137784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/03730A ZA202203730B (en) | 2019-09-13 | 2022-03-31 | Lassavirus vaccines |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12558410B2 (https=) |
| EP (1) | EP4041300A1 (https=) |
| JP (1) | JP7663250B2 (https=) |
| CN (1) | CN114728054A (https=) |
| AU (1) | AU2020346382A1 (https=) |
| BR (1) | BR112022004378A2 (https=) |
| WO (1) | WO2021048402A1 (https=) |
| ZA (1) | ZA202203730B (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005042014A1 (en) | 2003-10-29 | 2005-05-12 | The University Of Queensland | West nile virus vaccine |
| JP5779352B2 (ja) * | 2008-03-14 | 2015-09-16 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | 複製欠損フラビウイルスワクチンおよびワクチンベクター |
| GB201307528D0 (en) | 2013-04-26 | 2013-06-12 | Univ Leuven Kath | Bacterial artificial chromosomes |
| BR102016018430A2 (pt) * | 2016-08-10 | 2018-02-27 | Fundação Oswaldo Cruz | Cassete de expressão heteróloga, constructo de dna e composição vacinal para imunizar contra flavivírus e/ou outros patógenos. |
| WO2019018501A1 (en) | 2017-07-18 | 2019-01-24 | Geovax Inc. | COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE |
-
2020
- 2020-09-11 BR BR112022004378A patent/BR112022004378A2/pt unknown
- 2020-09-11 EP EP20767710.5A patent/EP4041300A1/en active Pending
- 2020-09-11 WO PCT/EP2020/075541 patent/WO2021048402A1/en not_active Ceased
- 2020-09-11 US US17/642,795 patent/US12558410B2/en active Active
- 2020-09-11 CN CN202080071104.5A patent/CN114728054A/zh active Pending
- 2020-09-11 JP JP2022516041A patent/JP7663250B2/ja active Active
- 2020-09-11 AU AU2020346382A patent/AU2020346382A1/en not_active Abandoned
-
2022
- 2022-03-31 ZA ZA2022/03730A patent/ZA202203730B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022004378A2 (pt) | 2022-06-07 |
| EP4041300A1 (en) | 2022-08-17 |
| CN114728054A (zh) | 2022-07-08 |
| US20220378903A1 (en) | 2022-12-01 |
| JP2022547695A (ja) | 2022-11-15 |
| US12558410B2 (en) | 2026-02-24 |
| JP7663250B2 (ja) | 2025-04-16 |
| AU2020346382A1 (en) | 2022-04-21 |
| WO2021048402A1 (en) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Trent et al. | Partial nucleotide sequence of St. Louis encephalitis virus RNA: structural proteins, NS1, ns2a, and ns2b | |
| Rochman et al. | Molecular adaptations during viral epidemics | |
| HUP0002139A2 (hu) | Kiméra flavivírus-vakcinák | |
| UA98620C2 (uk) | Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2 | |
| GR3032416T3 (en) | Chimeric and/or growth-restricted flaviviruses. | |
| EP3191589B1 (en) | Flavivirus virus like particle | |
| JP2016521553A5 (https=) | ||
| JP2011523347A5 (https=) | ||
| CA3099330A1 (en) | Synthetic chimeric vaccinia virus | |
| WO2011153351A3 (en) | Novel modified live-attenuated vaccines (mlv) and subunit vaccines created by dna shuffling against porcine reproductive and respiratory syndrome virus (prrsv) | |
| Maruggi et al. | Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity | |
| CA2914550C (en) | Avian cells for improved virus production | |
| WO2023056351A8 (en) | Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof | |
| CN103352029A (zh) | 一种乙脑/森林脑炎嵌合病毒及其应用 | |
| MX390966B (es) | Vacunas contra el dengue | |
| ZA202203730B (en) | Lassavirus vaccines | |
| WO2011038473A8 (pt) | Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos | |
| MX2022004220A (es) | Composición inmunogénica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteina spike del sars-cov-2. | |
| MX2021001901A (es) | Nucleotidos de codificacion del factor ix. | |
| JP2011523642A5 (https=) | ||
| Morrison et al. | Abrogation of TLR3 inhibition by discrete amino acid changes in the C-terminal half of the West Nile virus NS1 protein | |
| ZA202203731B (en) | Chimeric filovirus vaccines | |
| JP2006526393A5 (https=) | ||
| IL315248A (en) | A viral vector genome encoding an insulin fusion protein | |
| EP4265631A3 (en) | Live-attenuated flaviruses with heterologous antigens |